Skip to main content
Delfa

← All assets

Avagacestat

12 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

12

Ongoing

0

Recruiting

0

Completed

11

Sites

86

Countries

7

Endpoints

45

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 45 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
10
Phase 2
2

Trials by status

Completed
11
Terminated
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK
28
Other (unclassified)
10
Neuroimaging
4
Global cognition
1
Function / daily living
1
Disease progression
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 1 of 45 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

12 of 12

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
NCT00890890A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Avagacestat

Alzheimer’s disease

prodromal ADPh 2Terminated64Jul 20131
NCT00810147A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

Avagacestat

Alzheimer’s disease

mild-to-moderate ADPh 2Completed41Jun 20101
NCT01079819Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

Avagacestat

Alzheimer’s disease

Age ≥18Ph 1Completed3Dec 2010-
NCT01039194Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

Avagacestat

Alzheimer’s disease

Age 18-55Ph 1Completed1Apr 2010-
NCT00901498Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

Avagacestat

Alzheimer’s disease

Age 18-45Ph 1Completed1Jul 2009-
NCT00726726Drug Interaction Study With a Potential Alzheimer's Disease Compound

Avagacestat

Alzheimer’s disease

Age 18-45Ph 1Completed1Oct 2008-
NCT01042314Drug-Drug Interaction Study With Aricept® (Donepezil)

Avagacestat

Alzheimer’s disease

Age 18-55Ph 1Completed1Apr 2010-
NCT01057030Multiple Dose Japanese Bridging Study

Avagacestat

Alzheimer’s disease

Age 20-45Ph 1Completed1Jun 2010-
NCT01002079Drug-Drug Interaction Study With Rifampin

Avagacestat

Alzheimer’s disease

Age 18-55Ph 1Completed1Oct 2010-
NCT00979316Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects

Avagacestat

Alzheimer’s disease

Healthy volunteersPh 1Completed1Feb 2010-
NCT00860275Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole

Avagacestat

Alzheimer’s disease

Age 18-55Ph 1Completed1Jun 2009-
NCT01454115Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

Avagacestat

Alzheimer’s disease

Age ≥18Ph 1Completed0Mar 20091

Showing 1-12 of 12 trials